By Ben Butkus
Qiagen this week expanded its molecular diagnostics footprint by announcing its plans to acquire an undisclosed minority stake in Alacris Theranostics, a German startup company using bioinformatics to cull patients' genomic data for biomarkers that can be used to personalize cancer treatments.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
